The IBCSG 23-01 trial evaluated whether women with breast cancer and sentinel-node micrometastases could safely avoid completion axillary lymph-node dissection. Long-term follow-up showed no clinically important disadvantage in disease-free or overall survival for patients managed without axillary dissection. The study became an important foundation for reducing the extent of axillary surgery in selected early breast cancers. Its relevance is broader than the specific population studied: it illustrates how better staging and effective systemic and radiation therapies can allow surgeons to remove less tissue without compromising outcomes. For contemporary breast practice, the decision remains dependent on disease extent, tumor characteristics and the total treatment plan, but the evidence strongly supports avoiding routine additional axillary surgery when only limited sentinel-node disease is present and the patient meets appropriate criteria. Reduced axillary intervention can improve quality of life by lowering risks of lymphoedema, sensory disturbance and shoulder dysfunction. The trial therefore supports a patient-centered approach to breast cancer surgery in which “more surgery” is not automatically equated with “better cancer care.”